trending Market Intelligence /marketintelligence/en/news-insights/trending/FYnsTE6wyvWRXEviJqVGhA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Astellas Pharma's blood cancer drug Xospata wins EU approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Astellas Pharma's blood cancer drug Xospata wins EU approval

Japan's Astellas Pharma Inc. said the European Commission gave market approval to its blood cancer treatment Xospata, over a month after the regulator issued a positive opinion on the drug.

Xospata, or gilteritinib, was developed as a single therapy to treat adult patients whose acute myeloid leukemia with the FLT3 mutation has either returned or is unresponsive to treatment.

Acute myeloid leukemia is a type of fast-growing cancer in which too many immature white blood cells, known as myeloblasts, are found in the bone marrow and blood.

The EU approval is based on the results of a late-stage study, dubbed Admiral, in which patients who were given Xospata showed significantly higher average overall survival as compared to those given chemotherapy.

The drug received an accelerated assessment from the European Medicines Agency in February, resulting in the reduced time frame for the therapy's approval.

Xospata is also approved in the U.S. and Japan to treat adult patients with the same disorder.